CombiMatrix Says Q2 Revenues Decline 3.5 Percent; Gov't Contracts Shrink Though Sales Surge | GenomeWeb
NEW YORK (GenomeWeb News) - CombiMatrix yesterday said that second-quarter revenue declined 3.5 percent as R&D spending doubled and net losses narrowed slightly.
 
Total receipts for the three months ended June 30 declined to $1.79 million from $1.85 million in the year-ago period.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.